Does PEGASUS need a COMPASS to find optimal medical management? – reviewing options in high risk CVD patients
The UKCPA/JOMO study day has become the main event in the respiratory pharmacy calendar. Despite the challenges this year this speakers and sessions were excellent.
NHS attendee at the UKCPA/JOMO respiratory study day
|Satellite||Does PEGASUS need a COMPASS to find optimal medical management? – reviewing options in high risk CVD patients|
|Speakers||Paul Wright (Lead Cardiac Pharmacist - Cardiac Pharmacy Department, Barts Heart Centre, Barts Health NHS Trust)|
This session will touch of current practice for treatment options for those at high risk of CVD. We will explore previous trial data looking at extending DAPT therapy and explore new options – predominantly data for rivaroxaban 2.5mg twice daily (in the COMPASS trial) and from ticagrelor 60mg twice daily (from the PEGASUS trial). Finally we will explore options on how these strategies could be implemented at a local level.
Advanced level – knowledge of ACS and current treatment strategies required